This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Patricia Penovich, MD; John P. Morgan, MD; Boris Kerzner, MD; Fred Karch, MD; David Goldblatt, MD

JAMA. 1978;239(19):1997-1998.

Abstract
We administered deanol acetamidobenzoate, 2.0 g/day for four weeks, in a double-blind, placebo-controlled crossover trial, to 14 patients with tardive dyskinesia. The patient population included both inpatients and outpatients. The response was evaluated by subjective clinical impression and scoring of filmed sequences. Patients' conditions improved significantly from baseline scores while receiving both deanol and placebo, but there was no distinction between the two treatments.

(JAMA 239:1997-1998, 1978)

Author Affiliations
From the Departments of Pharmacology and Toxicology (Drs Penovich, Morgan, Kerzner, and Karch) and Neurology (Dr Goldblatt), University of Rochester School of Medicine and Dentistry, Rochester, NY.

Footnotes
Reprint requests to Sophie Davis Center for Biomedical Education, City College of the City University of New York, 138th St and Convent Ave, New York, NY 10031 (Dr Morgan).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Therapeutic Strategies Against Tardive Dyskinesia: Two Decades of Experience
Jeste and Jed Wyatt
Arch Gen Psychiatry 1982;39:803-816.
ABSTRACT